An investigation for investors in Theranos was announced following news reports that Theranos, Inc is the subject of a criminal probe by federal prosecutors and the Securities and Exchange Commission.
Those who are investors in the Series C rounds, or any other form of investing in Theranos, Inc have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether certain statements by Theranos, Inc. regarding its business, its prospects and its operations were materially false and misleading.
On April 13, 2016, it was reported that “federal health regulators have proposed banning Theranos Inc. founder Elizabeth Holmes from the blood-testing business for at least two years after concluding that the company failed to fix what regulators have called major problems at its laboratory in California.” Among other things, the regulators “found that Theranos failed to adequately correct 43 of 45 deficiencies identified by inspectors last year.”
On April 18, 2016,it was reported that federal prosecutors, with assistance from the FBI, had launched a criminal investigation “into whether Theranos Inc. misled investors about the state of its technology and operations.” As detailed in the article, federal officials requested information about Theranos in January and February, and followed those requests with “grand-jury subpoenas from a federal court in San Francisco in March.” In addition to the criminal probe, the article also reported that the SEC was “examining whether Theranos made deceptive statements to investors when it solicited funding.”
Those who are an investor in the Series C rounds, or any other form of investing in Theranos, Inc, have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com